|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US7878978B2
(en)
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
EP1874824A4
(en)
*
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
CN101374546B
(zh)
*
|
2005-12-16 |
2016-03-23 |
Ibc医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
AU2011292178B8
(en)
*
|
2006-12-05 |
2016-01-21 |
Ibc Pharmaceuticals, Inc. |
Compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. the therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody
|
|
WO2008088658A2
(en)
*
|
2007-01-17 |
2008-07-24 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
DE602007003314D1
(de)
*
|
2007-03-14 |
2009-12-31 |
Montco Cancer Res B V |
Immunmodulierendes Antikrebsmittel
|
|
CN101959429B
(zh)
|
2008-01-08 |
2014-09-10 |
阿克塞利亚制药公司 |
抗微生物肽系统的激动剂
|
|
US8034396B2
(en)
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
US9433579B2
(en)
*
|
2008-05-02 |
2016-09-06 |
Albert Wong |
Growth factor sensitive vesicle
|
|
JP5919604B2
(ja)
*
|
2008-08-08 |
2016-05-18 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
抗膵癌抗体
|
|
WO2010022225A1
(en)
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
US8877170B2
(en)
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
US8968733B2
(en)
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
US8663689B2
(en)
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
EP2416807A4
(en)
*
|
2009-04-10 |
2012-06-13 |
Immunomedics Inc |
NEW STRATEGIES FOR IMPROVED CANCER VACCINES
|
|
IN2012DN01331A
(https=)
*
|
2009-08-31 |
2015-06-05 |
Ibc Pharmaceuticals Inc |
|
|
JP6114936B2
(ja)
*
|
2009-08-31 |
2017-04-19 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法
|
|
AU2010315432A1
(en)
*
|
2009-11-05 |
2012-04-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
CA2781717C
(en)
*
|
2009-12-09 |
2017-09-12 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) complexes for delivery of interference rna
|
|
CA2782398C
(en)
|
2009-12-09 |
2017-09-26 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
CN102947341B
(zh)
*
|
2010-01-19 |
2018-07-06 |
哈佛大学校长及研究员协会 |
用于病原体检测和治疗的工程化调理素
|
|
CA2804263A1
(en)
|
2010-06-29 |
2012-01-12 |
Tyco Healthcare Group Lp |
Microwave-powered reactor and method for in situ forming implants
|
|
EP2588153A2
(en)
|
2010-07-01 |
2013-05-08 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
EP2635300A4
(en)
*
|
2010-11-03 |
2014-04-02 |
Ibc Pharmaceuticals Inc |
DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
|
|
US9417240B2
(en)
|
2011-05-27 |
2016-08-16 |
Drexel University |
Capped and conjugated quantum dots
|
|
BR112014004168A2
(pt)
*
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
|
CA2861335A1
(en)
*
|
2012-01-26 |
2013-08-01 |
Ibc Pharmaceuticals, Inc. |
Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
|
|
EP2854845B1
(en)
|
2012-06-01 |
2018-03-28 |
IBC Pharmaceuticals, Inc. |
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20150231241A1
(en)
*
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
RU2714733C2
(ru)
*
|
2013-03-15 |
2020-02-19 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Технологии мультимеризации
|
|
CN103333248B
(zh)
*
|
2013-06-07 |
2014-07-09 |
东南大学 |
一种cd25纳米抗体、其编码序列及应用
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
US9416197B2
(en)
|
2013-11-01 |
2016-08-16 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
|
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
SG11201706024YA
(en)
|
2015-01-26 |
2017-08-30 |
Macrogenics Inc |
Multivalent molecules comprising dr5-binding domains
|
|
WO2016191481A1
(en)
|
2015-05-28 |
2016-12-01 |
Immunomedics, Inc. |
T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
US20190133963A1
(en)
*
|
2015-11-03 |
2019-05-09 |
Nanoproteagen |
Polymeric nanoparticles
|
|
JP2018533590A
(ja)
*
|
2015-11-13 |
2018-11-15 |
ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター |
角膜障害の治療のためのプロテアソームモジュレーション
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
WO2017106627A1
(en)
|
2015-12-17 |
2017-06-22 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
|
TW201730212A
(zh)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
Ｒｏｒ１－結合分子及其使用方法
|
|
KR102508650B1
(ko)
|
2016-04-07 |
2023-03-13 |
더 존스 홉킨스 유니버시티 |
사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
KR102449406B1
(ko)
*
|
2016-08-02 |
2022-09-29 |
백시넥스 인코포레이티드 |
백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
|
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
|
IL268836B2
(en)
|
2017-02-24 |
2024-04-01 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
AU2018250641B2
(en)
*
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
SG11202005557TA
(en)
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
EP3759225A1
(en)
|
2018-03-02 |
2021-01-06 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
CN112469661B
(zh)
*
|
2018-06-13 |
2024-04-26 |
斯克里普斯研究学院 |
具有新结构组分的纳米粒疫苗
|
|
CN110872355B
(zh)
*
|
2018-08-29 |
2021-08-24 |
中国农业大学 |
抗金刚烷胺AMD单链抗体scFv及其制备方法与应用
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
US12252582B2
(en)
|
2019-08-29 |
2025-03-18 |
University Of Delaware |
Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
|
|
CN110964119A
(zh)
*
|
2019-12-05 |
2020-04-07 |
沣潮医药科技（上海）有限公司 |
抗疟二聚体免疫粘附素、药物组合物和用途
|
|
EP4106813A4
(en)
|
2020-02-21 |
2024-03-27 |
MacroGenics, Inc. |
CD137 BINDING MOLECULES AND THEIR USES
|
|
WO2021220053A2
(en)
|
2020-04-27 |
2021-11-04 |
Sixfold Bioscience Ltd. |
Compositions containing nucleic acid nanoparticles with modular functionality
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
CN112553256B
(zh)
*
|
2021-02-20 |
2021-06-22 |
北京百普赛斯生物科技股份有限公司 |
Il-2受体复合物及其制备方法与应用
|
|
CN120919285A
(zh)
*
|
2025-06-30 |
2025-11-11 |
复旦大学 |
一种口服多肽制剂及其制备方法
|